New antibody cocktail for COVID-19 passes early safety check
NCT ID NCT05181683
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 23 times
Summary
This early-phase study tested the safety of a combination of two antibodies (casirivimab and imdevimab) given as a shot or through an IV in 45 healthy adults or those with stable chronic conditions. The goal was to see if the treatment is safe and how the body processes it. No direct treatment benefit was measured, as this was a safety-focused trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Regeneron Study Site
Miami, Florida, 33186, United States
-
Regeneron StudySite
Winter Park, Florida, 32789, United States
Conditions
Explore the condition pages connected to this study.